$PSY

PSY

$18.55

Psychedelic ETF

No spam. We promise

PSY

Mental illnesses are on the rise and existing medications have been found wanting. A staggering 30% of depression patients do not respond to any currently available treatment.1 Research budgets for psychiatric medicine in large companies have fallen dramatically over the last decade, as confidence wanes that more investment in the same direction will produce improved results.2

Recent breakthrough studies in the medical repurposing of psychedelics and ketamine have found significant benefits to sufferers of anxiety, PTSD, OCD, eating disorders, depression and others. Declared a “breakthrough therapy,” by the FDA in 2018 and 2019, studies on the use of psilocybin have found rapid, marked, and enduring anti-anxiety and depression effects.

Invest in the Future of Psychedelics and Medical Cannabis

PSY is the first US-listed psychedelic ETF. It seeks to track the BITA Medical Psychedelics, Cannabis, and Ketamine Index, a rules-based index that tracks the performance of a portfolio of companies listed on North American Exchanges conducting legal activities under the national laws of the applicable country related to medical psychedelics, medical cannabis, cannabis pharmaceuticals and cannabidiol (“CBD”) derivatives, and ketamine.

Companies included in the index must have a minimum market capitalization of $75 million, and operate in the production, distribution, or services related to medical psychedelics, medical cannabis or other medicinal drugs and their derivatives.

1 “Compass Pathways (NASDAQ:CMPS) IPO Proves Psychedelic Medicine Investment Thesis, WPSS Investments Newswire,” October 1, 2020. https://www.globenewswire.com/news-release/2020/10/02/2102708/0/en/compass-pathways-nasdaq-cmps-ipo-proves-psyche%c2%acdelic-medicine-investment-thesis.html

2 “Big pharma pulling back from mental health drug research: studies,” October 29, 2012, https://www.ctvnews.ca/health/health-headlines/big-pharma-pulling-back-from-mental-health-drug-research-studies-1.1015154

Fund Data and Pricing

Net Assets $9.69M
Premium/discount 1.21%
NAV $19.38
Closing Price $19.61
Shares Outstanding 500,000
Median 30 Day Spread 0.41%
Data as of 09/17/2021

Fund Details

Fund inception 05/27/21
Ticker PSY
Primary Exchange NYSE
CUSIP 26922B808
Fund Holdings 21
NAV Symbol PSY.NV
Expense Ratio 0.75%
30 Day SEC Yield* -0.72%
* Yield as of 8/31/21
PSY
YTD1 Months3 Months6 Months1 YearSince Inception
Total Return (%) xx.xx% -7.86% -20.21% xx.xx% xx.xx% -17.13%
Market Price (%) xx.xx% -7.10% -19.83% xx.xx% xx.xx% -16.63%
1 YearSince Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD1 Months3 Months6 Months1 YearSince Inception
Total Return (%) xx.xx% -7.80% xx.xx% xx.xx% xx.xx% -10.06%
Market Price (%) xx.xx% -7.93% xx.xx% xx.xx% xx.xx% -10.26%
1 YearSince Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD1 Months3 Months6 Months1 YearSince Inception
Total Return (%) xx.xx% -6.07% xx.xx% xx.xx% xx.xx% -2.45%
Market Price (%) xx.xx% -6.27% xx.xx% xx.xx% xx.xx% -2.53%
1 YearSince Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
YTD1 Months3 Months6 Months1 YearSince Inception
Total Return (%) xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% 3.86%
Market Price (%) xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% 4.00%
1 YearSince Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Performance current to the most recent month-end can be obtained by calling 833.333.9383. Short term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns. Market price is the price at which shares in the ETF can be brought or sold on the exchanges during trading hours, while the net asset value (NAV) represents the value of each share’s portion of the fund’s underlying assets and cash at the end of the trading day.
NameSymbolStock price% Price change% Net assetsShares HeldMarket Value
Cardiol Therapeutics Inc-aCRDL CN $5.40 0.00% 5.52%126,400535,152
Compass Pathways PlcCMPS $32.10 -5.34% 5.32%15,560515,658
Forian IncFORA $20.00 -11.13% 5.29%44,580512,670
Gh Research PlcGHRS $0.00 -6.48% 5.13%23,500496,790
Atai Life Sciences NvATAI $15.82 -4.69% 5.11%30,160495,227
Zynerba Pharmaceuticals IncZYNE $4.26 -1.42% 5.07%116,000490,680
Seelos Therapeutics IncSEEL $1.92 -4.00% 4.96%240,100480,200
Pharmacielo LtdPCLO CN $1.23 0.00% 4.91%493,160475,587
Cronos Group IncCRON CN $7.59 0.00% 4.88%79,460472,854
Neptune Wellness Solutions Inc ComNEPT $0.58 -10.77% 4.85%722,560469,664
Data as of 09/20/2021. Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.
View full holdings
Download Fund Documents
Investment Case
Fact Sheet
Index Methodology Guide
Prospectus
Summary Prospectus
SAI
Semi-Annual Report
Premium Discount Graph

Reasons to Invest

Psychedelic future

Imagine if a non-addictive, short term intervention with minimal side effects could dramatically improve mental health? Psychedelics could be a part of such treatment.

Next Gen. Medicine

Psychedelics promote neural plasticity, essentially allowing the brain to rewire itself. Recipients report unparalleled insight and paradigm shifts akin to mystical or spiritual awakenings.

Growth Potential

Psilocybin, LSD and their derivatives could become an integral part of the multi-billion dollar global medicine market; offering hope to many whose conditions seem untreatable in current paradigms.

Marijuana

PSY also offers exposure to companies leading the medical repurposing of cannabis, to treat chronic pain, symptoms of MS, and side effects of chemotherapy among others.